3rd Sep 2026 11:20
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.
----------
Main Market small-cap winners
----------
Gem Diamonds Ltd, up 68% at 10.50 pence, swings to interim profit
SIG PLC, up 9.2% at 10.09p
Iconic Labs PLC, up 9.1% at 1.50p
Cykel AI PLC, up 7.3% at 19.00p
Petra Diamonds Ltd, up 6.7% at 6.24p
----------
Main Market small-cap losers
----------
abrdn European Logistics Income PLC, down 39% at 10.65p
Crest Nicholson Holdings Ltd, down 9.2% at 55.65p, cuts full-year outlook
abrdn Property Income Trust Ltd, down 7.9% at 1.75p
Bay Capital PLC, down 7.4% at 12.50p
London BTC Co Ltd, down 6.5% at 2.00p
----------
AIM winners
----------
Kazera Global PLC, up 24% at 1.95 pence, settles outstanding claims
Mothercare PLC, up 17% at 0.83p
Hutchmed China Ltd, up 17% at 210.00p, inks USD1.30 billion GSK deal for cancer drug
Jangada Mines PLC, up 11% at 0.75p
Tanfield Group PLC, up 10% at 4.75p
----------
AIM losers
----------
Futura Medical PLC, down 24% at 0.25p, looks to raise GBP150,000
Rome Resources PLC, down 13% at 0.23p
Forgent PLC, down 11% at 0.01p
Xeros Technology Group PLC, down 8.6% at 1.33p
GCM Resources PLC, down 7.5% at 15.50p
----------
Small-cap and AIM movers in focus:
----------
Gem Diamonds Ltd, up 68% at 10.50 pence, 12-month range 2.50p-12.00p. Swings to a first-half pretax profit of USD3.1 million from a USD20.0 million loss a year earlier, as revenue rises 32% to USD59.7 million from USD45.4 million. Says "encouragingly strong demand" supports an improvement in diamond prices, with the average price achieved increasing to USD1,395 per carat from USD1,008. Cost of sales rises to USD47.9 million from USD39.7 million.
----------
Crest Nicholson Holdings Ltd, down 9.2% at 55.65 pence, 12-month range 53.00p-176.20p. Cuts its full-year outlook following weaker-than-expected summer trading, now forecasting 1,350 to 1,400 completions compared with previous guidance of 1,400 to 1,500. Expects an adjusted loss before interest and tax of around GBP10 million, having previously guided for a profit of GBP5 million to GBP10 million, as affordability pressures, competitive pricing and weaker open-market demand weigh on sales. However, improves its year-end net debt forecast to between GBP70 million and GBP90 million from GBP100 million to GBP120 million, helped by its cash optimisation programme, a further fire remediation recovery and an additional land disposal. Says discussions with lenders over amendments to its debt covenants are continuing but have taken longer than originally expected.
----------
Hutchmed China Ltd, up 17% at 210.00 pence, 12-month range 150.48p-266.00p. Signs an exclusive licensing agreement with GSK PLC for worldwide rights outside Greater China to its experimental cancer treatment HMPL-A830. Hutchmed receives USD110 million upfront and is eligible for milestone and royalty payments of up to USD1.30 billion. HMPL-A830 targets cancers with KRAS gene mutations, which are common in colorectal, lung and pancreatic cancers, and is designed to improve the efficacy and durability of treatment. Hutchmed will develop the global phase one programme, which is expected to begin in the second half of 2026. Says the GSK deal marks a major milestone for its antibody-targeted therapy conjugate platform and could help unlock a new class of precision oncology medicines.
----------
Kazera Global PLC, up 24% at 1.95 pence, 12-month range 0.59p-1.80p. Agrees to pay USD1.0 million to settle outstanding claims from Fujax South Africa, describing the agreement as a positive resolution of a historic liability. Says its existing cash resources are sufficient to meet current obligations but would limit its capacity for further investment following the settlement. Is therefore considering an equity fundraising of around GBP500,000 to strengthen its balance sheet and support ongoing activities. Requests a temporary suspension of trading in its shares while it progresses the proposed fundraising.
----------
Futura Medical PLC, down 24% at 0.25 pence, 12-month range 0.21p-10.45p. Raises GBP1.6 million through a placing of 801.0 million new shares at 0.2p each and launches a mergers and acquisitions and formal sale process. Says proceeds will strengthen its working capital position and support the commercial development of erectile dysfunction treatment Eroxon. Also seeks to raise up to GBP150,000 through a retail offer at the same price. The placing is conditional on shareholder approval at a general meeting on September 23. Futura aims to explore potential M&A opportunities and progress the formal sale process around February 2027.
----------
By Eva Castanedo, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Gem Diamonds DiSIGIconic LabsPetra DiamondsCykel AiAbrdn Euro LogCrest NicholsonAbrdn PropertyBay CapitalLondon BtcHutchmedJangada MinesMothercareTanfieldGlaxosmithklineFutura MedicalRome Resources PLCForgentXeros TechGCM Resources